Innere Medizin (Heidelberg, Germany) · 2022
[Evidence of positive care effects by digital health apps-methodological challenges and approaches].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
König Inke R, Mittermaier Mirja, Sina Christian, Raspe Matthias, Stais Patrick, Gamstätter Thomas, Stachwitz Philipp, Wolfrum Sebastian, Richter Jutta G, Möckel Martin, Arbeitsgruppe Digitale Gesundheitsanwendungen (DiGA) und künstliche Intelligenz (KI) in Leitlinien der Kommission Digitale Transformation der Deutschen Gesellschaft für Innere Medizin (DGIM)
Аннотация
Since 2020, digital health applications (DiGA) can be prescribed at the expense of the German statutory health insurance (SHI) system after undergoing an approval procedure by the Federal Institute for Drugs and Medical Devices (BfArM). DiGA can be approved provisionally for 1 year (with the option of extension) or permanently. The latter is dependent on scientific evidence of a positive effect on care, which can be a medical benefit or a patient-relevant structural and procedural improvement in care. However, it is apparent that the investigation of DiGA in scientific studies is challenging, as they are often complex interventions whose success also includes user and prescriber factors. In addition, health services research data underpinning the benefits of DiGA are lacking to date. In the current article, methodological considerations for DiGA research are presented, and a selection of internal medicine DiGAs is used to critically discuss current research practice.